Memory T Cells in Vaccine-Induced Immunity for Infectious Diseases
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: 31 December 2026 | Viewed by 2138
Special Issue Editor
Interests: memory T cells; vaccination; adjuvant; immune strategy; infectious disease
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Memory T cells are essential for vaccine-induced immunity, providing long-lasting protection against infectious diseases such as tuberculosis, malaria, smallpox, COVID-19, and influenza. They are classified into three main types: Central Memory T Cells, Effector Memory T Cells, and Tissue-Resident Memory T Cells. Vaccines activate the adaptive immune system to generate memory T cells specific to the target pathogen. Upon re-exposure, these cells respond faster and more effectively than naïve T cells, limiting pathogen replication and reducing disease severity. Understanding the mechanisms that maintain memory T cells over time is vital for developing long-lasting vaccines. Advances in vaccine technologies, such as mRNA platforms and adjuvant design, are enhancing our ability to generate robust and durable memory T cell responses. In addition, efforts to target Tissue-Resident Memory T Cells are being explored, particularly for respiratory pathogens. Leveraging the biology of memory T cells and investigating the factors affecting the development of immune memory following vaccination will be critical for combating infectious diseases and improving global health outcomes.
Prof. Dr. Bingdong Zhu
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- memory T cells
- vaccination
- adjuvant
- immune strategy
- infectious disease
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
